UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Biology of blood and marrow transplantation, 2020-08, Vol.26 (8), p.e177-e182

2020

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity

Blood advances, 2018-08, Vol.2 (16), p.2095-2103

2018

Link zum Volltext

Verfügbarkeit prüfen

Understanding Health Care Costs in a Wisconsin Acute Leukemia Population

Journal of Patient-Centered Research and Reviews, 2016-08, Vol.3 (3), p.142-149

2016

Link zum Volltext

Verfügbarkeit prüfen

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.4044-4044

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Blood, 2021-11, Vol.138 (Supplement 1), p.410-410

2021

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States 2004–2014: A Generalized Additive Modeling Approach

PharmacoEconomics, 2020-05, Vol.38 (5), p.515-526

2020

Link zum Volltext

Verfügbarkeit prüfen

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Blood, 2019-11, Vol.134 (Supplement_1), p.764-764

2019

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Reimbursement and Service Utilization for One Year of Post-Allogeneic Hematopoietic Cell Transplantation (alloHCT) Care for Medicare Beneficiaries Ages 65 and Older with Acute Myeloid Leukemia

Blood, 2017-12, Vol.130, p.4695-4695

2017

Link zum Volltext

Verfügbarkeit prüfen

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization And Estimated Unmet Need among Medicare Beneficiaries with Acute Myeloid Leukemia

Transplantation and cellular therapy, 2022-09, Vol.28 (12), p.852-858

2022

Link zum Volltext

Verfügbarkeit prüfen

Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

Pediatric blood & cancer, 2021-08, Vol.68 (8), p.e29067-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach

PharmacoEconomics, 2020-05, Vol.38 (5), p.515-526

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT) outcomes

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7117-7117

2014

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell Disease

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S306

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population

Transplantation and cellular therapy, 2022-06, Vol.28 (6), p.325.e1-325.e7

2022

Link zum Volltext

Verfügbarkeit prüfen

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia

Transplantation and cellular therapy, 2022-12, Vol.28 (12), p.852-858

2022

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic Cell Transplant Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease

Transplantation and cellular therapy, 2021-04, Vol.27 (8), p.685.e1-685.e8

2021

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease

Transplantation and cellular therapy, 2021-08, Vol.27 (8), p.685.e1-685.e8

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(60)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Humans
(15)
Hematology
(12)
Transplantation
(11)
Immunology
(9)
Female
(6)
Male
(6)
Social Sciences
(6)
Adult
(5)
Animals
(5)
Biological And Medical Sciences
(5)
Hematopoietic Cell Transplantation
(5)
Hematopoietic Stem Cell Transplantation
(5)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(5)
Aged
(4)
Child
(4)
Education & Educational Research
(4)
Education, Scientific Disciplines
(4)
Health Care Sciences & Services
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Biology Of Blood And Marrow Transplantation
(12)
Transplantation And Cellular Therapy
(12)
Blood
(6)
Molecular And Cellular Biology
(3)
Blood Advances
(2)
Medical Teacher
(2)
Pharmacoeconomics
(2)
Academic Medicine
(1)
Animal Biotelemetry
(1)
Cell
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity

Understanding Health Care Costs in a Wisconsin Acute Leukemia Population

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States 2004–2014: A Generalized Additive Modeling Approach

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Healthcare Reimbursement and Service Utilization for One Year of Post-Allogeneic Hematopoietic Cell Transplantation (alloHCT) Care for Medicare Beneficiaries Ages 65 and Older with Acute Myeloid Leukemia

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization And Estimated Unmet Need among Medicare Beneficiaries with Acute Myeloid Leukemia

Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT) outcomes

Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell Disease

Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes

Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population

Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia

Hematopoietic Cell Transplant Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease

Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease

Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry

Suchergebnisse filtern